A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAFASITAMAB PLUS LENALIDOMIDE IN ADDITION TO RITUXIMAB VERSUS LENALIDOMIDE IN ADDITION TO RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA GRADE 1 TO 3A OR R/R MARGINAL ZONE LYMPHOMA (INMIND)

Registry ID

INCMOR 0208-301

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

INCYTE CORPORATION

Start date

2022-04-14

Last update

2021-03-31

Conditions

• LYMPHOMA

Related clinical trials

• A PHASE III, MULTICENTRE, OPEN-LABEL, RANDOMISED STUDY EVALUATING THE EFFICACY AND SAFETY OF R-MINI-CHOP × 2 FOLLOWED BY AZD0486 VERSUS R-MINI-CHOP × 6 IN ELDERLY OR UNFIT PARTICIPANTS WITH NEWLY DIAGNOSED LARGE B-CELL LYMPHOMA (SOUNDTRACK-D2)
• A PHASE 1 / 2, OPEN-LABEL STUDY OF REC-1245 IN PARTICIPANTS WITH UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC CANCER
• LORATADINE FOR THE PREVENTION OF BONE PAIN CAUSED BY GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) DURING STEM CELL MOBILIZATION
• SINGLE-ARM, PHASE 2 STUDY OF VALEMETOSTAT TOSYLATE MONOTHERAPY IN SUBJECTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA
• AN EXTENSION STUDY OF VENETOCLAX FOR SUBJECTS WHO HAVE COMPLETED A PRIOR VENETOCLAX CLINICAL TRIAL
• IDENTIFICATION AND EVALUATION OF PATIENTS AT RISK OF DEVELOPING CARDIOTOXICITY AFTER RECEIVING CHEMOTHERAPY FOR BREAST CANCER, LEUKEMIA OR LYMPHOMA

View on source registry